Larimar Therapeutics (LRMR) Non Operating Interest Expenses (2014 - 2020)

Larimar Therapeutics (LRMR) has reported Non Operating Interest Expenses for 7 consecutive years, with $301000.0 the latest figure, recorded in Q1 2020.

• For the quarter ending Q1 2020, Non Operating Interest Expenses fell 39.8% year-over-year to $301000.0; the trailing twelve-month figure through Mar 2020 stood at $1.6 million (down 19.23% YoY), and the FY2019 full-year result was $1.8 million, down 6.95% from the prior year.
• Non Operating Interest Expenses fell to $301000.0 in Q1 2020 per LRMR's latest filing, from $362000.0 in the prior quarter.
• Across five years, Non Operating Interest Expenses topped out at $500000.0 in Q1 2019 and bottomed at $8000.0 in Q4 2017.
• Historically, Non Operating Interest Expenses has averaged $274058.8 across 5 years, with a median of $301000.0 in 2020.
• The sharpest annual moves came in 2017 and 2018: Non Operating Interest Expenses slumped 91.75% in 2017, then surged 6137.5% in 2018.
• Over 5 years, Non Operating Interest Expenses stood at $97000.0 in 2016, then plunged by 91.75% to $8000.0 in 2017, then soared by 6137.5% to $499000.0 in 2018, then fell by 27.45% to $362000.0 in 2019, then dropped by 16.85% to $301000.0 in 2020.
• According to Business Quant data, Non Operating Interest Expenses over the past three periods registered $301000.0, $362000.0, and $426000.0 for Q1 2020, Q4 2019, and Q3 2019 respectively.